OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse NANTES, France, June 12, 2024 – ...
Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study Surgical resection plus adjuvant platinum-based chemotherapy ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- The ...
NEWBURYPORT — Newburyport’s Benjamin Besse took first place in the Elite/Open class at Sunday’s 8th annual DAM Sprint Triathlon in Amesbury, racing ahead of the field to finish in 1:03:11. The race ...
Although immunotherapy for advanced non–small cell lung cancer (NSCLC) is being lauded as game changing, the phenomenon of treatment-associated hyperprogressive disease (HPD) continues to serve as a ...
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). The Company’s current well-balanced first-in-class ...
Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study Surgical resection plus adjuvant platinum-based chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback